{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-011218","form_type":"8-K","ticker":"GANX","cik":"0001819411","company_name":"Gain Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.117213+00:00","generated_at":"2026-05-17T14:47:49.384053+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Gain Therapeutics Q2 net loss $0.19/sh; Phase 1b PD study fully enrolled, data by Q4 2025","bullets":["Phase 1b of GT-02287 in Parkinson's reached target enrollment in Q2 2025 with 16 patients; up to 20 total.","Functional and biomarker analysis from 90-day dosing expected in Q4 2025; extension request submitted.","Net loss per share $0.19 vs $0.42 YoY; R&D spend down to $2.8M on grant income and credit.","Cash $6.7M as of June 30; July 2025 public offering raised ~$7.1M net, extending runway past Phase 1b.","IND submission to FDA for GT-02287 expected by year-end 2025 to enable US Phase 2 expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-011218","json":"https://secwatch.observer/filing/0001558370-25-011218.json","markdown":"https://secwatch.observer/filing/0001558370-25-011218.md","text":"https://secwatch.observer/filing/0001558370-25-011218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/0001558370-25-011218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/ganx-20250812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:47:49.384053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}